VCNX RSI Chart
Last 7 days
-3.6%
Last 30 days
14.5%
Last 90 days
-46.5%
Trailing 12 Months
-93.1%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 124.0K | 0 | 0 | 0 |
2023 | 825.0K | 825.0K | 795.0K | 570.0K |
2022 | 0 | 0 | 100.0K | 325.0K |
2021 | 1.5M | 1.5M | 900.0K | 900.0K |
2020 | 0 | 0 | 1.1M | 1.0M |
2019 | 612.0K | 511.0K | 717.0K | 523.0K |
2018 | 248.5K | 407.0K | 565.5K | 724.0K |
2017 | 0 | 0 | 0 | 90.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 19, 2024 | friedberg albert | bought | 1,333 | 4.73 | 282 | - |
Mar 28, 2024 | zauderer maurice | acquired | 300,000 | 7.77 | 38,610 | president and ceo |
Mar 28, 2024 | friedberg albert | acquired | 799,999 | 7.77 | 102,960 | - |
Feb 08, 2024 | zauderer maurice | acquired | 300,000 | 0.725 | 413,793 | president and ceo |
Feb 08, 2024 | friedberg albert | acquired | 1,200,000 | 0.725 | 1,655,170 | - |
Dec 26, 2023 | van strydonck, gerald e. | sold | -2,267 | 0.72 | -3,149 | - |
Dec 08, 2023 | van strydonck, gerald e. | sold | -893 | 0.67 | -1,334 | - |
Oct 04, 2023 | zauderer maurice | bought | 4,865 | 0.973 | 5,000 | president and ceo |
Oct 03, 2023 | zauderer maurice | bought | 500,000 | 1.00 | 500,000 | president and ceo |
Oct 03, 2023 | friedberg albert | bought | 3,000,000 | 1.00 | 3,000,000 | - |
Which funds bought or sold VCNX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | Tower Research Capital LLC (TRC) | sold off | -100 | -4,426 | - | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | sold off | -100 | -3.00 | - | -% |
May 15, 2024 | MORGAN STANLEY | new | - | 8,248 | 8,248 | -% |
May 15, 2024 | MORGAN STANLEY | sold off | -100 | -13.00 | - | -% |
May 15, 2024 | Point72 Asset Management, L.P. | new | - | 863,606 | 863,606 | -% |
May 15, 2024 | Royal Bank of Canada | new | - | - | - | -% |
May 15, 2024 | Royal Bank of Canada | sold off | -100 | - | - | -% |
May 15, 2024 | TWO SIGMA INVESTMENTS, LP | sold off | -100 | -10,743 | - | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | new | - | 7,743 | 7,743 | -% |
May 14, 2024 | Tacita Capital Inc | new | - | 1,689 | 1,689 | -% |
Unveiling Vaccinex Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Vaccinex Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Vaccinex Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 |
Revenue | - | 104,000 | - | 20,000 | - | 550,000 | 225,000 | 50,000 | - | 50,000 | - | 850,000 | - | 625,000 | - | 404,000 | 25,000 | 94,000 | 194,000 | 198,000 | 126,000 | 206,000 |
Cost Of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 2,000 | - | 8,000 | 16,000 | 175,000 | 301,000 | 246,000 | 246,000 | 240,000 |
Costs and Expenses | 3.8% | 5,178,000 | 4,988,000 | 5,854,000 | 7,077,000 | 5,536,000 | 5,344,000 | 4,842,000 | 5,518,000 | 5,113,000 | 5,669,000 | 7,090,000 | 6,089,000 | 9,208,000 | 6,339,000 | 8,082,000 | 8,883,000 | 9,234,000 | 8,755,000 | 6,652,000 | 6,683,000 | - |
S&GA Expenses | -100.0% | - | 1,631,000 | 1,499,000 | 2,027,000 | 1,724,000 | 1,603,000 | 1,413,000 | 1,564,000 | 1,484,000 | 1,605,000 | 1,577,000 | 1,840,000 | 1,872,000 | 1,928,000 | 1,531,000 | 1,563,000 | 1,647,000 | 1,381,000 | 1,092,000 | 925,000 | 1,221,000 |
R&D Expenses | 0.8% | 3,383,000 | 3,357,000 | 4,355,000 | 5,050,000 | 3,812,000 | 3,741,000 | 3,429,000 | 3,954,000 | 3,629,000 | 4,064,000 | 5,513,000 | 4,249,000 | 7,334,000 | 4,411,000 | 6,543,000 | 7,304,000 | 7,412,000 | 7,073,000 | 5,314,000 | 5,512,000 | - |
EBITDA Margin | -335.4% | -154 | -35.40 | -27.52 | -26.29 | -24.22 | -60.32 | -191 | -23.80 | -25.37 | -17.86 | -18.42 | -27.26 | - | - | - | - | - | - | - | - | - |
Interest Expenses | - | - | - | 500 | - | - | -500 | 1,000 | -16,000 | 142,000 | 351,000 | 332,000 | 339,000 | 148,000 | - | - | - | - | - | 44,000 | 81,000 | 267,000 |
Income Taxes | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings Before Taxes | -15.8% | -3,897,000 | -3,366,000 | -4,912,000 | -7,060,000 | -4,962,000 | -5,078,000 | -4,759,000 | -4,651,000 | -5,206,000 | -5,969,000 | -6,574,000 | -6,446,000 | -8,754,000 | -6,326,000 | -7,642,000 | -8,828,000 | -9,067,000 | -8,449,000 | -6,599,000 | -6,608,000 | - |
EBT Margin | -335.6% | -155 | -35.61 | -27.69 | -26.50 | -24.46 | -60.97 | -193 | -24.89 | -26.88 | -18.81 | -19.17 | -28.04 | - | - | - | - | - | - | - | - | - |
Net Income | -17.5% | -3,897,000 | -3,317,000 | -4,912,000 | -7,060,000 | -4,962,000 | -5,078,000 | -4,759,000 | -4,631,000 | -5,206,000 | -5,969,000 | -6,574,000 | -6,446,000 | -8,754,000 | -6,326,000 | -7,642,000 | -8,828,000 | -9,067,000 | -8,449,000 | -6,599,000 | -6,608,000 | - |
Net Income Margin | -335.5% | -154 | -35.53 | -27.69 | -26.50 | -24.46 | -60.97 | -193 | -24.87 | -26.88 | -18.81 | -19.17 | -28.04 | - | - | - | - | - | - | - | - | - |
Free Cashflow | -26.6% | -4,600,000 | -3,634,000 | -3,118,000 | -5,500,000 | -5,049,000 | -4,597,000 | -4,195,000 | -5,145,000 | -6,069,000 | -6,981,000 | -7,113,000 | -6,346,000 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | 102.9% | 7,367 | 3,631 | 2,558 | 3,085 | 4,895 | 7,977 | 8,612 | 12,572 | 18,121 | 9,843 | 15,189 | 23,789 | 30,684 | 11,702 | 18,725 | 3,099 | 4,881 | 4,604 | 10,810 | 7,121 | 13,294 |
Current Assets | 113.6% | 7,154 | 3,349 | 2,206 | 2,679 | 4,418 | 7,478 | 8,025 | 12,261 | 17,766 | 9,405 | 14,862 | 23,442 | 30,313 | 11,286 | 18,237 | 2,574 | 4,269 | 4,010 | 10,309 | 6,566 | 12,750 |
Cash Equivalents | 93.6% | 2,972 | 1,535 | 127 | 1,908 | 3,323 | 6,391 | 7,186 | 11,400 | 16,803 | 8,589 | 13,741 | 22,385 | 29,389 | 10,596 | 17,092 | 526 | 2,491 | 2,776 | 8,578 | 5,279 | 5,279 |
Net PPE | -19.1% | 110 | 136 | 164 | 177 | 207 | 189 | 236 | 254 | 256 | 297 | 327 | 347 | 371 | 416 | 488 | 525 | 612 | 594 | 501 | 555 | 544 |
Liabilities | -20.7% | 4,712 | 5,942 | 6,427 | 3,508 | 2,495 | 2,784 | 2,294 | 1,629 | 1,933 | 2,431 | 3,299 | 6,849 | 7,903 | 14,314 | 14,961 | 8,677 | 6,620 | 6,878 | 6,896 | 9,501 | 6,959 |
Current Liabilities | -20.5% | 4,706 | 5,916 | 6,362 | 3,383 | 2,310 | 2,537 | 1,987 | 1,491 | 1,777 | 2,256 | 2,165 | 5,715 | 6,769 | 13,180 | 13,827 | 7,543 | - | 6,878 | - | - | - |
Long Term Debt | -76.9% | 6.00 | 26.00 | 44.00 | 63.00 | 82.00 | 101 | 119 | 138 | 156 | 175 | 1,134 | 1,134 | 1,134 | 1,134 | 1,134 | 1,134 | - | - | - | - | - |
LT Debt, Current | 1.3% | 76.00 | 75.00 | 75.00 | 75.00 | 75.00 | 74.00 | 74.00 | 74.00 | 74.00 | 74.00 | - | - | - | - | - | - | - | - | - | - | - |
LT Debt, Non Current | -100.0% | - | 26.00 | 44.00 | 63.00 | 82.00 | 101 | 119 | 138 | 156 | 175 | 1,134 | 1,134 | 1,134 | 1,134 | 1,134 | 1,134 | - | - | - | - | - |
Shareholder's Equity | 214.9% | 2,655 | -2,311 | - | - | 2,400 | 5,193 | 6,318 | 10,943 | 16,188 | 7,412 | 11,890 | 16,940 | 22,781 | - | 3,765 | - | - | - | 3,914 | - | 6,335 |
Retained Earnings | -1.2% | -343,824 | -339,900 | -336,610 | -331,698 | -324,638 | -319,700 | -314,600 | -309,800 | -304,500 | -299,861 | -295,200 | -290,000 | -284,055 | -277,481 | -271,034 | -262,280 | -255,779 | -248,630 | -242,304 | -234,662 | -225,834 |
Additional Paid-In Capital | 2.3% | 345,253 | 337,627 | 332,752 | 331,279 | 327,044 | 324,880 | 320,923 | 320,789 | 320,651 | 307,281 | 307,128 | 306,972 | 284,881 | 250,914 | 250,843 | 232,748 | 230,086 | 222,403 | 222,265 | 208,329 | 208,216 |
Shares Outstanding | 38.0% | 1,232 | 893 | 347 | 313 | 261 | 238 | 197 | 194 | 185 | 147 | 147 | 128 | 120 | 107 | - | - | - | - | - | - | - |
Minority Interest | - | - | - | - | - | - | - | - | - | - | - | - | - | 21,963 | 23,963 | 23,963 | 23,963 | 23,963 | 23,963 | 23,963 | 23,963 | 23,963 |
Float | - | - | - | - | 10,420 | - | - | - | 25,255 | - | - | - | 47,747 | - | - | - | 23,671 | - | - | - | 23,013 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -26.6% | -4,600 | -3,634 | -3,100 | -5,500 | -5,000 | -4,599 | -4,146 | -5,333 | -4,996 | -5,145 | -6,059 | -6,982 | -7,114 | -6,347 | -9,342 | -5,448 | -7,510 | -5,803 | -10,490 | -5,946 | -8,476 |
Share Based Compensation | -7.7% | 96.00 | 104 | 115 | 126 | 129 | 132 | 134 | 138 | 141 | 153 | 156 | 128 | 104 | 71.00 | 91.00 | 366 | 204 | 138 | 137 | 113 | 60.00 |
Cashflow From Investing | - | - | - | -18.00 | - | -49.00 | 2.00 | -49.00 | - | - | - | -10.00 | - | - | 1.00 | -37.00 | - | -254 | - | -10.00 | 2,283 | 11,800 |
Cashflow From Financing | 21.4% | 6,069 | 5,000 | 1,332 | 4,092 | 2,021 | 3,802 | -19.00 | -18.00 | 13,210 | -9.00 | -2,575 | - | 25,907 | -115 | 25,910 | 3,483 | 7,479 | - | - | - | - |
Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||
Revenue | $ 104,000 | $ 550,000 |
Costs and expenses: | ||
Research and development | 3,383,000 | 3,812,000 |
General and administrative | 1,795,000 | 1,724,000 |
Total costs and expenses | 5,178,000 | 5,536,000 |
Loss from operations | (5,074,000) | (4,986,000) |
Financing costs - warrant liabilities | (28,000) | |
Change in fair value of warrant liabilities | 1,206,000 | 0 |
Other income (expense), net | (1,000) | 24,000 |
Loss before provision for income taxes | (3,897,000) | (4,962,000) |
Provision for income taxes | 0 | 0 |
Net loss attributable to Vaccinex, Inc. common stockholders | (3,897,000) | (4,962,000) |
Comprehensive loss | $ (3,897,000) | $ (4,962,000) |
Net loss per share attributable to Vaccinex, Inc. common stockholders, basic | $ (2.94) | $ (20.89) |
Net loss per share attributable to Vaccinex, Inc. common stockholders, diluted | $ (2.94) | $ (20.89) |
Weighted-average shares used in computing net loss per share attributable to Vaccinex, Inc. common stockholders, basic | 1,327,257 | 237,527 |
Weighted-average shares used in computing net loss per share attributable toVaccinex, Inc. common stockholders, diluted | 1,327,257 | 237,527 |
Condensed Balance Sheets (Unaudited) - USD ($) | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 2,972,000 | $ 1,535,000 |
Accounts receivable | 2,775,000 | 961,000 |
Prepaid expenses and other current assets | 1,312,000 | 853,000 |
Derivative asset | 95,000 | |
Total current assets | 7,154,000 | 3,349,000 |
Property and equipment, net | 110,000 | 136,000 |
Operating lease right-of-use asset | 103,000 | 146,000 |
TOTAL ASSETS | 7,367,000 | 3,631,000 |
Current liabilities: | ||
Accounts payable | 2,329,000 | 2,039,000 |
Accrued expenses | 1,880,000 | 1,242,000 |
Deferred revenue | 59,000 | 63,000 |
Current portion of long-term debt | 76,000 | 75,000 |
Operating lease liability | 103,000 | 146,000 |
Warrant liability | 259,000 | 2,351,000 |
Total current liabilities | 4,706,000 | 5,916,000 |
Long-term debt | 6,000 | 26,000 |
TOTAL LIABILITIES | 4,712,000 | 5,942,000 |
Commitments and contingencies (Note 6) | ||
Stockholders’ equity (deficit): | ||
Convertible preferred stock (Series A), par value of $0.001 per share; 10,000,000 shares authorized, 10 shares issued and outstanding as of March 31, 2024, and no shares authorized, issued or outstanding as of December 31, 2023; with aggregate liquidation preference of $1,750,000 and $0 as of March 31, 2024 and December 31, 2023, respectively | 1,236,000 | 0 |
Common stock, par value of $0.0001 per share; 100,000,000 shares authorized as of March 31, 2024, and December 31, 2023; 1,584,305 and 892,622 shares issued as of March 31, 2024 and December 31, 2023, respectively;1,584,300 and 892,617 shares outstanding as of March 31, 2024 and December 31, 2023, respectively | 1,000 | 0 |
Additional paid-in capital | 345,253,000 | 337,627,000 |
Treasury stock, at cost; 5 shares of common stock as of March 31, 2024 and December 31, 2023, respectively | (11,000) | (11,000) |
Accumulated deficit | (343,824,000) | (339,927,000) |
TOTAL STOCKHOLDERS' EQUITY/(DEFICIT) | 2,655,000 | (2,311,000) |
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ 7,367,000 | $ 3,631,000 |